Immunocytokines for Cancer Immunotherapy

Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma

1994 • 747 citations

Vascular leak syndrome: a side effect of immunotherapy

1997 • 260 citations

Cytokines and Immune Response in the Tumor Microenvironment

2001 • 250 citations

The development and clinical use of trastuzumab (Herceptin).

2002 • 189 citations

Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells.

1992 • 179 citations

A Phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma

1997 • 154 citations

T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy.

1996 • 152 citations

Synergy between an antiangiogenic integrin α_vantagonist and an antibody–cytokine fusion protein eradicates spontaneous tumor metastases

1999 • 128 citations

A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice.

1994 • 103 citations

An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response.

1996 • 99 citations

Immunocytokines

1998 • 99 citations

Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy.

1997 • 94 citations

Antibody-IL-12 Fusion Proteins Are Effective in SCID Mouse Models of Prostate and Colon Carcinoma Metastases

1998 • 93 citations

Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins.

1996 • 93 citations

Antibody–cytokine fusion proteins for the therapy of cancer

2001 • 81 citations

Antidisialoganglioside/granulocyte macrophage–colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcγRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis

2002 • 76 citations

Interleukin 1 Trials in Cancer Patients: A Review of the Toxicity, Antitumor and Hematopoietic Effects

1996 • 74 citations

Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer

2002 • 74 citations

Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy.

1996 • 73 citations

Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors.

1999 • 64 citations

Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12

1999 • 54 citations

Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents.

2001 • 54 citations

Mechanisms of leukocyte-mediated tissue injury induced by interleukin-2

1999 • 52 citations

The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro.

1999 • 51 citations

T Cell Memory Against Colon Carcinoma Is Long-Lived in the Absence of Antigen

1999 • 51 citations

Recent developments in immunotoxin therapy

1994 • 48 citations

The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy.

2001 • 46 citations

A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors

2001 • 43 citations

Melanoma immunotherapy by targeted IL-2 depends on CD4+ T-cell help mediated by CD40/CD40L interaction

2000 • 42 citations

Pharmacokinetics and stability of the ch14.18-interleukin-2 fusion protein in mice

1999 • 42 citations

Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2

1996 • 41 citations

ANTIBODY-DIRECTED, EFFECTOR CELL-MEDIATED TUMOR DESTRUCTION

2001 • 40 citations

Antibody-interleukin 2 fusion proteins: A new approach to cancer therapy

1996 • 38 citations

Targeting cancer with radiolabeled antibodies

1995 • 38 citations

Suppression of human prostate carcinoma metastases in severe combined immunodeficient mice by interleukin 2 immunocytokine therapy.

1998 • 37 citations

Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.

1997 • 31 citations

Recent advances in immunotherapy and monoclonal antibody treatment of cancer

2000 • 24 citations

Immunocytokines

1997 • 21 citations

Cytotoxic functions of blood mononuclear cells in patients with colorectal carcinoma treated with mAb 17-1A and granulocyte/macrophage-colony-stimulating factor

1992 • 20 citations

Specific Enzyme-Linked Immunosorbent Assays for Quantitation of Antibody-Cytokine Fusion Proteins

1999 • 19 citations

Applications of monoclonal antibodies in clinical oncology

1994 • 18 citations

Therapy of Colorectal Carcinoma with Monoclonal Antibodies (MAb17-1A) Alone and in Combination with Granulocyte Monocyte-Colony Stimulating Factor (GM-CSF)

1991 • 17 citations

Use of interleukin-2 in advanced renal carcinoma: meta-analysis and review of the literature

2001 • 16 citations

Monoclonal antibodies in solid tumours: approaches to therapy with emphasis on gynaecological cancer

1998 • 8 citations

Cited By (0)

Loading...